HIMS
Hims & Hers Health, Inc.
There isn't enough reported data to score HIMS yet.
RPRX
Royalty Pharma plc
RPRX's fundamentals are mixed, but it looks expensive: trading at 45x earnings, about twice its usual 23x. Its downside scenario is about seven times its upside.
HIMS Fundamentals
| Metric | Status |
|---|---|
| Strong | |
| Weak | |
| Stable | |
| Strong |
HIMS's revenue and balance sheet are currently strong, and its cash flow is stable, but its profitability is weak.
RPRX Fundamentals
| Metric | Status |
|---|---|
| Healthy | |
| Healthy | |
| Strong | |
| Weak |
RPRX's revenue, profitability and cash flow are currently healthy, but its balance sheet is weak.
HIMS PE Valuation
HIMS has no meaningful PE right now: it lost money over the past year.
RPRX PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Forward | 12x | $68.97 | — |
| Cheap | 15x | $22.76 | -67% |
| Fair | 23x | $34.85 | -49% |
| Expensive | 44x | $66.74 | -3.2% |
| Current | 45x | $68.97 | — |
Historical ranges are pointers, not guarantees.
RPRX's PE is in its expensive range at 45x. If earnings grow as analysts expect, today's price would be 12x next year's earnings, in its cheap range.
HIMS Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Turning to a loss | |
| Strong growth | |
| Stable | |
| Limited | |
| Low |
Analysts expect HIMS's revenue to grow, but its earnings to decline. However, they disagree widely on these estimates.
RPRX Forward outlook
| Metric | Outlook |
|---|---|
| Strongly improving | |
| Strong growth | |
| Stable | |
| -- | |
| Limited | |
| High |
Analysts expect RPRX's earnings to grow, with its revenue and profitability holding steady.
HIMS Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q3 2026 | -$0.83 | -257% |
| Q2 2026 | -$0.63 | -180% |
| Q1 2026 | -$0.09 | -113% |
| Q4 2025 | $0.51 | -3.8% |
| Q3 2025 | $0.53 | +20% |
| Q2 2025 | $0.79 | +888% |
| Q1 2025 | $0.68 | +$0.69 |
| Q4 2024 | $0.53 | +$0.64 |
HIMS has swung to a loss: it lost $0.83 per share over the past year, after a profit the year before.
RPRX Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $5.95 | +292% |
| Q3 2026 | $1.52 | -13% |
| Q2 2026 | $1.87 | -18% |
| Q1 2026 | $1.90 | -22% |
| Q4 2025 | $1.78 | -6.8% |
| Q3 2025 | $1.75 | -32% |
| Q2 2025 | $2.29 | +52% |
| Q1 2025 | $2.45 | +38% |
| Q4 2024 | $1.91 | -25% |
RPRX has the edge over HIMS on earnings quality, reporting a profit while its opponent remains loss making.
HIMS Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $890.4M | +49% |
| Q2 2026 | $753.2M | +38% |
| Q1 2026 | $608.1M | +3.8% |
| Q4 2025 | $617.8M | +28% |
| Q3 2025 | $599M | +49% |
| Q2 2025 | $544.8M | +73% |
| Q1 2025 | $586M | +111% |
| Q4 2024 | $481.1M | +95% |
HIMS has the edge over RPRX on sales, with more consistent year-over-year improvement.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | -7.4% | -9.4 points |
| Q2 2026 | -13% | -18 points |
| Q1 2026 | -13% | -23 points |
| Q4 2025 | 1.5% | -2.4 points |
| Q3 2025 | 2% | -3.6 points |
| Q2 2025 | 4.9% | +1.4 points |
| Q1 2025 | 9.9% | +6.3 points |
| Q4 2024 | 3.9% | +4 points |
HIMS's operating margin was −7.4% last quarter, down 9.4 points from the same quarter a year ago.
RPRX Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $690.1M | +13% |
| Q2 2026 | $674.1M | +16% |
| Q1 2026 | $630.6M | +11% |
| Q4 2025 | $622M | +4.8% |
| Q3 2025 | $609.3M | +7.9% |
| Q2 2025 | $578.7M | +7.7% |
| Q1 2025 | $568.2M | 0% |
| Q4 2024 | $593.6M | -0.4% |
RPRX's revenue has grown year over year for seven quarters in a row: $690M last quarter, up 13% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 60% | -11 points |
| Q2 2026 | 20% | -17 points |
| Q1 2026 | 89% | -4.7 points |
| Q4 2025 | 62% | +1.5 points |
| Q3 2025 | 70% | -60 points |
| Q2 2025 | 36% | -14 points |
| Q1 2025 | 94% | +107 points |
| Q4 2024 | 61% | -42 points |
RPRX has the edge over HIMS on profitability, with a higher operating margin.
HIMS Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $26M | -67% |
| Q2 2026 | -$68.2M | +$1.3M |
| Q1 2026 | $53.1M | +5.9% |
| Q3 2025 | $79.3M | -7% |
| Q2 2025 | -$69.5M | -230% |
| Q1 2025 | $50.1M | +94% |
| Q3 2024 | $85.3M | +238% |
| Q2 2024 | $53.6M | +219% |
HIMS has the edge over RPRX on cash flow, with more consistent year-over-year improvement.
RPRX Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $686.1M | -2.4% |
| Q2 2026 | $728.5M | +100% |
| Q1 2026 | $718.2M | +20% |
| Q4 2025 | $827.1M | +11% |
| Q3 2025 | $702.6M | -0.1% |
| Q2 2025 | $364M | -45% |
| Q1 2025 | $596.1M | -10% |
| Q4 2024 | $742.5M | -3.9% |
RPRX's free cash flow has been positive every quarter for six years: $3B over the past year, up 23% from the year before.
HIMS Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +0.9% | +2.1M shares |
| 1 year | -6% | -14.9M shares |
| 3 years | +11% | +23.7M shares |
| 5 years | +17% | +33.8M shares |
HIMS has the edge over RPRX on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q4 2025 | $80.5M |
| Q3 2025 | $9.5M |
| Q2 2025 | — |
| Q1 2025 | — |
| Q4 2024 | $5M |
| Q3 2024 | $30M |
| Q2 2024 | $19.9M |
| Q1 2024 | $28.1M |
RPRX Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | 0% | +105K shares |
| 1 year | -0.5% | -2.6M shares |
| 3 years | -7.3% | -44.1M shares |
| 5 years | -8.3% | -50.1M shares |
| Available history | +58% | +205M shares |
RPRX has 557M diluted shares, about the same as a year ago.
| Quarter | Spent |
|---|---|
| Q3 2026 | $86.3M |
| Q2 2026 | $44.6M |
| Q1 2026 | $50.1M |
| Q4 2025 | $80.5M |
| Q3 2025 | $146.5M |
| Q2 2025 | $291.6M |
| Q1 2025 | $708.8M |
| Q4 2024 | $52.6M |
RPRX spent $262M buying back its own shares over the past year, down 78% from the year before.
HIMS Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q1 2026 | -5.9x | Net Cash |
| Q4 2025 | -1.4x | Net Cash |
| Q3 2025 | -2.2x | Net Cash |
| Q2 2025 | -7.3x | Net Cash |
| Q1 2025 | -2.1x | Net Cash |
| Q4 2024 | -2.8x | Net Cash |
| Q3 2024 | -2.9x | Net Cash |
| Q2 2024 | -5.5x | Net Cash |
HIMS has more cash than debt.
RPRX Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | 5.4x | High |
| Q2 2026 | 5.4x | High |
| Q1 2020 | 2.2x | Moderate |
| Q4 2019 | 2.2x | Moderate |
RPRX's net debt is about 5.4 years of its operating earnings (EBITDA).
HIMS Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 36.0 | Neutral |
| Stochastic | 23.0 | Neutral |
HIMS's weekly RSI is 36 (neutral) and its Stochastic is 23 (neutral).
RPRX Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 74.0 | Overbought |
| Stochastic | 89.9 | Overbought |
RPRX's weekly RSI is 74 (overbought) and its Stochastic is 90 (overbought).
HIMS PE vs Healthcare Sector
| Metric | HIMS | Sector median | Relative |
|---|---|---|---|
| PE | N/A | 26x | — |
HIMS has no meaningful PE right now: it lost money over the past year.
RPRX PE vs Healthcare Sector
| Metric | RPRX | Sector median | Relative |
|---|---|---|---|
| PE | 45x | 26x | 76% above |
| PE % | 84 | 31 | 53 pts above |
RPRX is trading at 45x earnings, a 76% premium to the Healthcare sector's median of 26x.
HIMS Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $27.3 | 28% below |
| 20 week MA | $29.2 | 32% below |
| 50 week MA | $27.7 | 29% below |
| 100 week MA | $35.9 | 45% below |
| 200 week MA | $24.4 | 19% below |
HIMS is in a downtrend: it's below all five of its weekly moving averages, and 19% below its 200-week average.
RPRX Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $62.6 | 10% above |
| 20 week MA | $60.4 | 14% above |
| 50 week MA | $52.2 | 32% above |
| 100 week MA | $43.1 | 60% above |
| 200 week MA | $36.5 | 89% above |
RPRX has the edge over HIMS on trend strength, trading above more of its moving averages.
HIMS Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $9.89 | $15.0 | +51% |
| 2021 | $15.0 | $6.65 | -56% |
| 2022 | $6.65 | $6.43 | -3.3% |
| 2023 | $6.43 | $8.90 | +38% |
| 2024 | $8.90 | $26.6 | +198% |
| 2025 | $26.6 | $34.3 | +29% |
| 2026 YTD | $34.3 | $19.7 | -42% |
HIMS's yearly returns have swung widely, from +198% in 2024 to −56% in 2021. It's down 42% so far in 2026.
RPRX Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $49.0 | $48.9 | -0.2% |
| 2021 | $48.9 | $40.3 | -18% |
| 2022 | $40.3 | $39.4 | -2% |
| 2023 | $39.4 | $28.1 | -29% |
| 2024 | $28.1 | $25.5 | -9.1% |
| 2025 | $25.5 | $39.2 | +54% |
| 2026 YTD | $39.2 | $69.0 | +76% |
RPRX has the edge over HIMS on returns for 2026, with the stronger performance.